ARV Therapies and Therapeutic Strategies

REPORTING ON EACS 2015

Comprehensive Expert Review and Discussion of Key Presentations

An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
The coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.

TURQUOISE-I Study: Use of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin in Patients with HCV/HIV-1 Co-infection on Stable Darunavir-containing Antiretroviral Therapy

P. Ruane, O. Adeyemi, R. Trinh, J. Lalezari, L. Bhatti, J. Slim, M. Ramgopal, R. Brennan, M.K. Jain, A. Khatri, M. Co, K. Robinson-Morgan, Y.B. Hu, L.M. Fredrick, N.S. Shulman, M. Saag, D. Wyles

Abstract LBPS7/1

TURQUOISE-I Part 1b: Study Design (N = 22)



Ruane P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS7/1.

TURQUOISE-I Part 1b: Patient Demographics and Baseline Characteristics

	DRV QD + OBV/PTV/r + DSV + RBV (n=10)	DRV BID + OBV/PTV/r + DSV + RBV (n=12)
Male, n (%)	8 (80)	9 (75)
Race, n (%)		
White	7 (70)	5 (42)
Black	3 (30)	6 (50)
Hispanic or Latino ethnicity, n (%)	3 (30)	3 (25)
Age, median (range), years	56 (44 – 65)	53 (34 – 68)
Body mass index, median (range), kg/m^2	26 (21 – 31)	26 (22 – 38)
HCV genotype 1a, n (%)	9 (90)	6 (50)
IL28B non-CC genotype, n (%)	10 (100)	10 (83)
Cirrhosis, n (%)	0	4 (33)
Treatment-naïve, n (%)	7 (70)	12 (100)
Treatment-experienced, n (%)		
Null responder	2 (20)	0
Partial responder	1 (10)	0
DRV as first protease inhibitor, n (%)	3 (30)	4 (33)
CD4+ cell count, median (range), /mcl	656 (283 – 1100)	612 (151 – 1317)

Ruane P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS7/1.

TURQUOISE-I Part 1b: Overall ITT SVR Rates



■ DRV QD + OBV/PTV/r + DSV + RBV

■ DRV BID + OBV/PTV/r + DSV + RBV

All patients to date remain HCV RNA undetectable

Ruane P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS7/1.

TURQUOISE-I Part 1b: Darunavir Pharmacokinetics

Pharmacokinetic Parameters (units)	DRV QD + OBV/PTV/r + DSV + RBV (n=10)	DRV BID + OBV/PTV/r + DSV + RBV (n=12)
C_{max} (ng/mL)	1.07 (0.933, 1.229)	0.928 (0.746, 1.155)
AUC (ng*h/mL)	0.93 (0.829, 1.043)	0.878 (0.699, 1.102)
C_{trough} (ng/mL)	0.46 (0.249, 0.852)	0.713 (0.519, 0.98)

- No apparent relationship between patient DRV Ctrough exposures and intermittent HIV-1 viremia was observed
  - 2 and 3 patients from the DRV QD and BID arms, respectively, experienced “blips” of intermittent HIV-1 viremia (Plasma HIV-1 RNA ≥40 and <200 copies/mL) during the treatment period
  - The highest HIV-1 RNA recoded during the treatment period was 79 copies/mL

Ruane P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS7/1.

TURQUOISE-I Part 1b: Treatment-Emergent Adverse Events

Event, n (%)	DRV QD + OBV/PTV/r + DSV + RBV (n=10)	DRV BID + OBV/PTV/r + DSV + RBV (n=12)
Any TEAE	10 (100)	10 (83)
TEAEs leading to study drug discontinuation	0	0
Any serious TEAE	0	1 (8)[a]
Any severe TEAE	1 (10)[b]	0
Common TEAEs in >10% of overall patient population		
Fatigue	4 (40)	4 (33)
Hemoglobin decreased	1 (10)	4 (33)
Irritability	3 (30)	2 (17)
Nausea	2 (20)	2 (17)
Anemia	1 (10)	2 (17)
Bronchitis	3 (30)	0
Decreased appetite	1 (10)	2 (17)
Diarrhea	1 (10)	2 (17)
Headache	2 (20)	1 (8)

aOne patient experienced colitis and dehydration, both considered not related to study drugs.
bOne patient had the severe AE of arthralgia, which was considered not related to study drugs.

Ruane P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS7/1.

TURQUOISE-I Part 1b: Laboratory Assessments

Event, n (%)	DRV QD + OBV/PTV/r + DSV + RBV (n=10)	DRV BID + OBV/PTV/r + DSV + RBV (n=12)
Alanine aminotransferase >5 x ULN	0	0
Aspartate aminotransferase >5 x ULN	0	0
Alkaline phosphatase >5 x ULN	0	0
Total bilirubin >3 x ULN	0	0
Hemoglobin		
<10 – 8 g/dL	1 (10)	3 (25)
<8 g/dL	0	1 (8)

Ruane P, et al; 15th EACS, Barcelona, Spain, October 21-24, 2015; Abst. LBPS7/1.